“فايزر” للأدوية تعلن فعالية لقاحها ضد كورونا بنسبة تفوق الـ٩٠٪
New York: Pfizer Inc. and BioNTech SE announced Monday that their COVID-19 vaccine candidate demonstrated efficacy against the virus above 90 percent in participants without prior evidence of infection.
These results were based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the two companies’ Phase 3 clinical study.
A statement from Pfizer said that the case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90 percent, at 7 days after the second dose. This meant that participants became immune after 28 days from when they were first vaccinated. The vaccine is taking over two doses, and the DMC did not report any serious safety concerns.
The Phase 3 clinical trial of the vaccine began on July 27 and has enrolled 43,538 participants to date, 38,955 of whom have received a second dose of the vaccine candidate as of November 8, 2020.
“Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccines ability to prevent COVID-19,” Pfizer Chairman and CEO Dr. Albert Bourla said.
Further testing of efficacy and safety will need to be conducted before the Food and Drug Administration (FDA) can approve the vaccine.